Skip to main content
. 2015 Apr 1;1(2):103–110. doi: 10.1016/S2055-6640(20)30484-2

Table 2.

Double-blind randomised controlled trials for entecavir: 48-week results

Trial HBeAg Endpoint Entecavir 0.5 mg OD (%) Lamivudine 100 mg OD (%)
ETV-022 [57] Positive HBV DNA
<300 copies/mL
236/354 (67%) 129/355 (36%)
ETV-027 [58] Negative HBV DNA
<300 copies/mL
293/325 (90%) 225/313 (72%)

P values for all results in table are <0.001. More than 80% of patients in both studies were treatment naïve, with similar proportions in both arms